Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells

Documenti analoghi

• Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity
  di: Callan D. Wesley, et al.
  Pubblicazione: (2024-10-01)
• Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
  di: Min Seung Lee, et al.
  Pubblicazione: (2021-02-01)
• Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
  di: Sergei Vyacheslavovich Semochkin, et al.
  Pubblicazione: (2019-01-01)
• Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system
  di: Shuyue Li, et al.
  Pubblicazione: (2026-01-01)
• Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
  di: Marta Pelon, et al.
  Pubblicazione: (2024-03-01)